
The first possible medicament from Danish biotechnology and contract research organization Gubra's partnership with Germany's Boehringer Ingelheim has now entered its first clinical trial phase, the latter informs in a press statement.
Here, the first healthy human subject has received a dose of the drug called GUB002496 in phase I trials, resulting in a milestone payment made to Gubra.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app